Recombinant Human AREG Protein，His

AREG, or Amphiregulin, is an epidermal growth factor (EGF) family member that plays a crucial role in various physiological processes, including cell proliferation, differentiation, and tissue repair. It has garnered significant interest in cancer research due to its involvement in tumor growth and progression, particularly in cancers such as breast and colon cancer. AREG is often overexpressed in various tumor types, promoting the activation of the EGF receptor (EGFR) signaling pathway, which is associated with enhanced cellular motility and invasion. In addition to its oncogenic properties, AREG is implicated in the development of the pulmonary system and wound healing processes, highlighting its dual role in both normal and pathological conditions. The study of AREG involves the exploration of its molecular mechanisms, regulatory pathways, and interactions with other growth factors and receptors. Understanding these elements is essential for developing targeted therapies, particularly in the context of EGFR inhibitors, which have shown efficacy in certain cancers but often face challenges due to resistance mechanisms that involve AREG. Continued research into AREG's structure-function relationships, its role in tumor microenvironments, and potential as a therapeutic target is vital for advancing both cancer treatment and regenerative medicine. This is further emphasized by the need for novel biomarkers in cancer diagnostics and prognostics, as AREG levels could serve as a predictive indicator of treatment response. Consequently, the investigation of AREG and its recombinant forms not only enhances our basic understanding of cell signaling and growth regulation but also opens avenues for innovative therapeutic strategies in oncology and other diseases where AREG is a critical player.